AbbVie Inc (ABBV)

66.23
NYSE : Health Care
Prev Close 64.72
Day Low/High 65.15 / 66.40
52 Wk Low/High 45.45 / 70.79
Avg Volume 9.05M
Exchange NYSE
Shares Outstanding 1.62B
Market Cap 104.68B
EPS 3.20
P/E Ratio 19.44
Div & Yield 2.28 (3.50%)

Latest News

AbbVie Is Still Pointed Up, for Now

AbbVie Is Still Pointed Up, for Now

Consider raising your sell stop protection to a close below $61.

S&P 500 on Track for July Gains as Alphabet, Amazon Climb

S&P 500 on Track for July Gains as Alphabet, Amazon Climb

The S&P 500 moves higher on Friday, on track to end the month on a high, as Alphabet and Amazon rally on positive earnings.

Trending Tickers: BUD, ABBV, SRCL, EXPE

Trending Tickers: BUD, ABBV, SRCL, EXPE

The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.

Abbvie Plans to Defend Humira, Sees Upside in Oncology and Hep C Treatments

Abbvie Plans to Defend Humira, Sees Upside in Oncology and Hep C Treatments

The company reported better-than-expected earnings and revenue Friday.

S&P 500 and Nasdaq Turn Higher as Alphabet Leads, Exxon Falls

S&P 500 and Nasdaq Turn Higher as Alphabet Leads, Exxon Falls

Stocks fluctuate on Friday morning as the mix of earnings reports again pulls Wall Street in two directions.

Stock Futures Mixed as Second-Quarter U.S. Growth Falls Short

Stock Futures Mixed as Second-Quarter U.S. Growth Falls Short

Stock futures are mixed on Friday morning after second-quarter economic growth in the U.S. falls short of economists' expectations.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

Alphabet shares rise after the company handily beats quarterly estimates; Amazon's cloud computing business continues to shine; U.S. stock futures point lower.

AbbVie (ABBV) Stock Up After Q2 Beat

AbbVie (ABBV) Stock Up After Q2 Beat

AbbVie (ABBV) stock is rising in pre-market trading this morning after the company posted better-than-expected second quarter results before today's market open.

AbbVie Announces Initiation Of Phase 3 Study Of Venetoclax In Patients With Relapsed Or Refractory Multiple Myeloma

AbbVie Announces Initiation Of Phase 3 Study Of Venetoclax In Patients With Relapsed Or Refractory Multiple Myeloma

- Trial will study efficacy and safety of venetoclax in combination with bortezomib and dexamethasone in patients who are considered sensitive or naive to proteasome inhibitors who have received 1 to 3 prior lines of therapy for multiple myeloma(1)

Earnings Post-Mortems and Previews

We check in on eight companies that already have reported results and three others that will report in the next couple weeks.

3 Stocks Pushing The Health Care Sector Downward

3 Stocks Pushing The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

The company's hepatitis C drug division is expected to see losses in the second half of the year.

What to Look for When AbbVie (ABBV) Reports Q2 Results

What to Look for When AbbVie (ABBV) Reports Q2 Results

AbbVie (ABBV) will report 2016 second quarter earnings on Friday before the market open.

Top 10 Dividend Aristocrats to Buy at a Discount Now

Top 10 Dividend Aristocrats to Buy at a Discount Now

These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.

Buy Gilead Sciences While It's Wallowing

Buy Gilead Sciences While It's Wallowing

It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.

AbbVie Receives U.S. FDA Approval Of Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C

AbbVie Receives U.S. FDA Approval Of Once-Daily VIEKIRA XR™ (dasabuvir, Ombitasvir, Paritaprevir And Ritonavir) For The Treatment Of Genotype 1 Chronic Hepatitis C

- New extended-release formulation is the first all-oral, co-formulated treatment containing the three direct-acting antiviral components of VIEKIRA PAK® for adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

- Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific antibody...

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

- The CHMP opinion represents a positive advance toward approval of the 12-week regimen of VIEKIRAX with ribavirin for genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with or without compensated cirrhosis

Do the Math! Stocks Are Poised for a Fall

Do the Math! Stocks Are Poised for a Fall

Optimism is warranted over the long haul, but investors probably face a short-term headache. Here are the crucial numbers and events to watch in the week ahead.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

AbbVie Payout Reminder; Buy Today

Don't miss strong performer ABBV's $0.57 dividend.

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Jefferies estimates Xiidra could yield revenue of $1.5 billion within five years of its launch.